Advocacy Win for Asthma Patients: Protecting Access to Clinician-Administered Biologics
October 13, 2022
Tezepelumab is a novel severe asthma treatment that was approved for clinician administration in late 2021. After a few months on the market, however, several Medicare Administrative Contractors made the unprecedented decision to place tezepelumab, a biologic approved for physician administration, on the Self-Administered Drug list.
Categorized in: Policy Papers, White Papers